Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Success and safety of high infliximab trough levels in inflammatory bowel disease

(2018) David Drobne et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

(2017) Magali Lemaitre et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

(2016) M J Casanova et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

313 Long-Term Outcome After Infliximab Withdrawal for Sustained Remission in Crohn's Disease

(2016) Catherine Reenaers et al.   GASTROENTEROLOGY

Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission

(2016) Aurélien Amiot et al.   Clinics and Research in Hepatology and Gastroenterology

Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

(2016) Theodora Bejan-Angoulvant et al.   Arthritis & Rheumatology

Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease

(2015) S. Paul et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal

(2015) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery

(2015) Cheryl Lau et al.   ANNALS OF SURGERY

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

(2015) Sarah S. Thomas et al.   BIODRUGS

Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission

(2015) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease

(2015) David Drobne et al.   Clinical Gastroenterology and Hepatology

Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases

(2015) Carla Felice et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Could therapeutic drug monitoring of anti-TNF-α be useful to consider a de-escalation of treatment?

(2015) Mathurin Flamant et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn’s Disease

(2015) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation

(2015) Martin Bortlik et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease

(2014) C. J. M. Williams et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

(2012) Mirthe Emilie van der Valk et al.   GUT

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY